About the Journal

SKIN is a peer-reviewed, open access, online only journal dedicated to providing free access globally to disseminate dermatological knowledge. Authors retain copyright in their articles, licensing publication of their content through use of Creative Commons CCBY license. The journal does not charge fees, and is supported by the National Society for Cutaneous Medicine. 


Read More

Current Issue

Vol. 8 No. 4 (2024): July 2024 Issue

Published: 2024-07-23

ISSUE HIGHLIGHTS

In-Depth Reviews

Off-Label Uses of Upadacitinib

Shivkar Amara, Ariana Sapoznik, Sophie Guenin, Nilesh Kodali, Mark Lebwohl

Page 1614-1643

PDF

Original Research

 A Retrospective Review of 22 patients on Anifrolumab in Refractory Cutaneous Lupus

Elliott Herron, Lauren Graham, Andrew Fortugno

Page 1644-1653

PDF

The Effect of Platelet Rich Plasma (PRP) Plus Microneedling Versus Tranexamic Acid Plus Microneedling in the Biometric Characteristics of Melasma: A Before-After, Assessor Analysis, Blinded, Clinical Trial

Masoumeh Roohaninasab, Mohammad Ali Nilforoushzadeh, Zahra Ebrahimi, Azadeh Goodarzi, Abolfazl Abouei, Elham Ziaeifar, Sona Zare, Maryam Nouri, Samaneh Mozafarpoor, Roya Zeinali

Page 1654-1665

PDF KOL SUMMARY

What Do Clinicians Mean When Submitting a Biopsy as “Rule Out Eczema”

Kaycee Nguyen, Clay Cockerell

Page 1666-1671

PDF

Review of Tumor Margins for Lentigo Maligna with Staged Surgical Excision and Permanent Section en face Processing

Michael Adkison, Andrew Armenta, Frank Winsett, Richard Wagner

Page 1672-1680

PDF

Medical Education in Dermatology

Perspectives Regarding Virtual Interviewing for Dermatology Residency in the United States: A Survey of Applicants, Residents, Faculty, and Program Directors in the 2022-2023 Application Cycle

Thomas Norman, Jana Guenther, Marie D. Lafeir, Scott Worswick

Page 1681-1695

PDF

Research Letters

Pain Management of Refractory Hidradenitis Suppurativa: Case Report

Aaron Burshtein, Paul Shekane

Page 1696-1699

PDF

Representation of Skin Color, Disease Severity, and Anatomic Location in Hidradenitis Suppurativa Images

Devea R. De, Sarah E. Park, Terri Shih, Vivian Y. Shi, Jennifer L. Hsiao

Page 1700-1704

PDF

Dermatology Education for Medical Students: Assessing Participation Rates in Clinical Dermatology Electives

Ashima Agarwal, Dr. Lauryn M. Falcone, Dr. Emily D. Cai, Dr. Alaina J. James

Page 1705-1707

PDF

Improvement of Vestibular Neuritis in a Patient with Psoriatic Arthritis following Ixekizumab Administration

Sherry Ershadi, Shivkar Amara , Dr. Mark Lebwohl

Page 1708-1710

PDF

Editorials

Treating Chronic Pruritus: Are We at the Threshold of a Breakthrough?

Payton Smith

Page 1711-1713

PDF

Brief Articles

A Case of Nevoid Hyperkeratosis of the Nipple in a Male Bahraini Patient

McKenzie A. Dirr, Sara Alkhanaizi , Fatema Khamdan

Page 1714-1718

PDF

Acrodermatitis Enteropathica Following a Pull-Through Procedure

Foday Koroma, Hayden Fung, Shivkar Amara, Mark Lebwohl

Page 1719-1722

PDF

Pityriasis Rubra Pilaris Following Administration of the Pfizer-BioNTech COVID-19 Vaccine Successfully Treated with Acitretin and Dupilumab

Raquel Hoopes, Ellen de Moll

Page 1723-1727

PDF

Drug-Induced Sweet’s Syndrome by Xcopri

Summer Wong, Chris Kowalczyk, Rehan Karim, Stanley Skopit, Francisco Kerdel

Page 1728-1731

PDF

Relapsing Polychondritis Masquerading as Auricular Pseudolymphoma: Case Report and Literature Review

Faraz Yousefian, DO, Mary Michael, DO, Sujitha Yadlapati, MD, Emily Sedaghat, MD, Brad Glick, DO, MPH, FAAD

Page 1732-1736

PDF

Use of Upadacitinib to Treat Atopic Dermatitis Refractory to Dupilumab in Elderly Patients

Mary Hren, Saakshi Khattri

Page 1737-1741

PDF

Successful Treatment of Refractory Discoid Lupus Erythematosus with Deucravacitinib

Alice Sohn, Nicole Bouché, George Michael Lewitt, Eingun James Song

Page 1742-1746

PDF

Significant Improvement of Persistent Hailey-Hailey Disease with Dupilumab: A Case Report

Malvika Ramesh, MD, Brinda Chellappan, MD, Lindy Ross, MD

Page 1747-1751

PDF

Successful Tralokinumab Treatment for Hand and Foot Atopic Dermatitis in a Patient with Skin of Color: A Case Report

Porcia Love, Chloe J. Walker, MD, MHS

Page 1752-1756

PDF

Use of Topical Minocycline for Treatment of Confluent and Reticulated Papillomatosis

Shannon Meledathu, Helen Nguyen, Zain Husain

Page 1757-1760

PDF

Steatocystoma Multiplex Suppurativa Treated Successfully with Adalimumab and Topical Tofacitinib

Mariana McCune, Aaron Graff, Christina Harview, Lindsay Ackerman

Page 1761-1764

PDF

Zosteriform Atrophoderma of Pasini and Pierini: A Case Report

Kaitlin Fields, Amena Alkeswani, Maria Tirado, Allison Jones

Page 1765-1768

PDF

Erythema Elevatum Diutinum in Association with IgA Monoclonal Gammopathy of Undetermined Significance

Katie De Jong, Mojahed Shalabi, Dale Schaefer

Page 1769-1773

PDF

SKINmages: Clinical Images in Dermatology

Hypertrophic Lichen Planus Due to Koebnerization After Percutaneous Vascular Procedure

Rama Abdin, Navina DeLight , James Del Rosso , Douglas Hansen, Naiem T. Issa

Page 1774-1776

PDF

Posters from 2024 PANP Conference: Psoriasis

Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials

Kenneth B. Gordon, Diamant Thaçi, Melinda Gooderham, Yukari Okubo, Bruce Strober, Luke Peterson, Delphine Deherder, José M. López Pinto, Paolo Gisondi

Page s404

PDF

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data

Andrew Blauvelt, Howard Sofen, Jo Lambert, Joseph F. Merola, Mark Lebwohl, Kim Hoyt, Subhashis Banerjee, Thomas Scharnitz, Jeffrey J. Crowley

Page s405

PDF

Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimchi Morita, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Matthew J. Colombo, John Vaile, Eleni Vritzali, Kim Hoyt, Carolin Daamen, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s406

PDF

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

Bruce Strober, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew F. Alexis, Diamant Thaci, Mark Lebwohl, Naiem T. Issa, Michael C. Cameron

Page s407

PDF

Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program

Mark Lebwohl, Richard B. Warren, Shinichi Imafuku, Jerry Bagel, April W. Armstrong, Thierry Passeron, Subhashis Banerjee, Matthew J. Colombo, Thomas Scharnitz, Kim Hoyt, Diamant Thaci, Andrew Blauvelt

Page s408

PDF

Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial

Alice Gottlieb, Bruce Strober, Georgios Kokolakis, Joseph Merola, Min Zheng, Richard Langley; Min Tang; Patrick Hofmann, Christian Thoma; Richard Warren

Page s409

PDF

Low Occurrence of Predefined Safety Events Across Six Randomized Clinical Trials of Spesolimab in Dermatologic Conditions

Kenneth Gordon, Kilian Eyerich, Milan Anadkat, Siew Eng Choon, Boni Elewski, Jonathan Barker, Arash Mostaghimi, Ming Tang, Thomas Haeufel, Christian Thoma, Diamant Thaci

Page s410

PDF

Atopic Dermatitis

Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age in Two Pivotal Phase 3 Trials

Andrew F. Alexis, Leon Kircik, Raj Chovatiya, Zakiya P. Rice, Tina Bhutani, Philip M. Brown, Stephen C. Piscitelli, David S. Rubenstein, Anna M. Tallman, April W. Armstrong

Page s411

PDF

Stability of Long-Term Therapeutic Responses to Tralokinumab in Adults with Moderate-to-Severe Atopic Dermatitis

Andrew Blauvelt, Chih-ho Hong, Ketty Peris, Norito Katoh, Marie Tauber, Mahreen Ameen, Melinda Gooderham, Christian Bjerregård Øland, Ann-Marie Tindberg, Le Gjerum, Kristian Reich

Page s412

PDF

Atopic Dermatitis Treatment with Topical Therapy Alone Results in Persistent Elevated Disease Severity and High Disease Control Dissatisfaction: Real-World Health Care Professional and Patient Perspectives

Peter Lio, Alexandra Golant, Raj Chovatiya, Bob Geng, Louise Ann DeLuca-Carter, Zach Dawson, Evangeline Pierce, James Haughton, Peter Anderson, James Piercy, Linda Stein-Gold

Page s413

PDF

Acne & Rosacea

Therapeutic Recommendations for the Treatment of Acne Vulgaris in the US

James Q. Del Rosso, Leon H. Kircik, Emil A. Tanghetti, Zoe D. Draelos, April Armstrong, Valerie D. Callender, Neal Bhatia, Steven R Feldman

Page s414

PDF

Impact of Age on Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants with Moderate-to-Severe Acne

Leon H. Kircik, Julie C. Harper, Hilary Baldwin, Lawrence F. Eichenfield, Emil A. Tanghetti, Emmy Graber, Heather C. Woolery-Lloyd, Zoe D. Draelos

Page s415

PDF

Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: Comparison of 4 Clinical Trials

Leon Kircik, Zoe D. Draelos, Michael Gold, Neil Sadick, Neal Bhatia

Page s416

PDF
View All Issues